Using tiny internal antibodies to block LINE‑1 proteins linked to brain diseases
Official title: Development of a novel model to study the effects of LINE-1 retrotransposons in disease and normal physiology using nanobodies
Funded at Mercer University Macon · NIH-11143936 · Data updated 2026-11-12
Researchers are creating tiny antibody tools to block LINE‑1 proteins that may play a role in Alzheimer’s and related conditions.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mercer University Macon NIH-funded |
| Lab location | 1 site (Macon, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $211,485 |
| NIH project number | 5R21GM155785-02 |
| Project ID | NIH-11143936 on NIH RePORTER |
Who could benefit from this research
✓Could help
People with Alzheimer’s disease, Aicardi‑Goutières syndrome, or other conditions where LINE‑1 activity is suspected may be future beneficiaries or candidates for follow‑on clinical studies.
✕Less likely to help
People seeking immediate treatment or those with conditions unrelated to LINE‑1 activity are unlikely to get direct benefit from this basic lab project.
What this research studies
If you or a loved one has Alzheimer’s disease or a related condition, this project aims to make tiny internal antibodies (nanobodies) that can bind to LINE‑1 proteins inside cells and turn them off. The team will use phage display to find high‑affinity nanobodies, then test those nanobodies in lab models to see how blocking LINE‑1 proteins changes cell behavior. The goal is to produce a reliable lab model to separate harmful LINE‑1 effects from normal biology and to enable clearer follow-up studies. This is preclinical laboratory work and would be an early step toward possible future treatments rather than a direct therapy today.
Why it matters
Potential benefit: If successful, this work could create new tools that speed the development of targeted therapies for diseases where LINE‑1 activity contributes to damage, like some dementias and inflammatory brain disorders.
How similar studies have gone: This is a novel approach: reliable knockdown of LINE‑1 proteins using intracellular nanobodies has not been widely established before.
Where this research is happening
-
Mercer University Macon
Macon, United States Active
Researchers
- Principal investigator: Cook, Pamela — Mercer University Macon
- Study coordinator: Cook, Pamela
Related research
Other NIH-funded projects on the same topics.
-
Role of a long noncoding RNA in normal biology and kidney cancer
A cancer-related long noncoding RNA called CRNDE is studied to understand how it affects normal body functions and the development of cancer, with a focus on kidney cancer.
-
Investigating the role of long noncoding RNA in cancer development and progression
This study is looking at how certain molecules called long noncoding RNAs might affect the growth of kidney cancer, specifically renal cell carcinoma, to find new ways to treat it.
-
Investigating how LINE-1 retrotransposons affect diseases and normal body functions using specialized antibodies.
This study is looking at how certain genetic elements called LINE-1 can affect diseases like Alzheimer's and autism, and they're trying to create a new way to target these elements using tiny antibodies, which could help improve treatments for patients.
-
Using deep learning and Raman spectroscopy for early cancer diagnosis
This study is trying to see if a new deep learning tool using blood samples can help spot early signs of different types of cancer, like colorectal and gastric cancers, in both healthy people and those already diagnosed.
-
Using brain stimulation to improve learning and decision-making
This study is testing if a type of brain stimulation can help healthy adults learn better and make smarter decisions.
-
Using MRI to guide brain stimulation for memory improvement
This study is testing a new way to boost memory by using MRI scans to guide brain stimulation for people with mild cognitive impairment and healthy individuals.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.